ReviewJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2012
Current management and recommendations for access to antiviral therapy of herpes labialis.
Review in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Comparison of photobiomodulation therapy with conventional treatment in patients with herpes labialis: a systematic review and meta-analysis of randomized controlled trials.Lasers in medical science · 2025Pooled it
- Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis.Journal of evidence-based integrative medicineTrial
- Clinical guidelines for herpes labialis: recommendations and quality evaluation according to AGREE II.Acta odontologica latinoamericana : AOL · 2024Review
- A Comprehensive Overview of Epidemiology, Pathogenesis and the Management of Herpes Labialis.Viruses · 2023Review
- Natural Polyphenol-Containing Gels against HSV-1 Infection: A Comparative Study.Nanomaterials (Basel, Switzerland) · 2022Article
- Disturbed Yin-Yang balance: stress increases the susceptibility to primary and recurrent infections of herpes simplex virus type 1.Acta pharmaceutica Sinica. B · 2020Review
- Pharmacy-Based Assessment and Management of Herpes Labialis (Cold Sores) with Antiviral Therapy.Innovations in pharmacy · 2020Article
- Stratum Corneum Sampling to Assess Bioequivalence between Topical Acyclovir Products.Pharmaceutical research · 2019Article
- Chemical composition and anti-herpes simplex virus type 1 (HSV-1) activity of extracts from Cornus canadensis.BMC complementary and alternative medicine · 2017Article
- Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study.Human vaccines & immunotherapeutics · 2016Article
- Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase.Nucleic acids research · 2016Review
- Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways.Antiviral research · 2016Article
- The use of local concentrated heat versus topical acyclovir for a herpes labialis outbreak: results of a pilot study under real life conditions.Clinical, cosmetic and investigational dermatology · 2013Article
- Management of Resistant Herpetic Whitlow: A Case of Recurrent Herpetic Whitlow Resistant to Standard Therapy.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 3 countries.
Funding
Abstract
Herpes labialis is a common skin infective condition, worldwide, which is primarily caused by HSV-1. Recurrent episodes of herpes labialis, also known as cold sores, can be frequent, painful, long-lasting and disfiguring for infected patients. At present, there are two types of antivirals for the treatment of herpes labialis, topical and oral, which are available over the counter or as prescription-only. The aim of antiviral therapy is to block viral replication to enable shortening the duration of symptoms and to accelerate healing of the lesions associated with herpes labialis. This review examines the evidence for the effectiveness of current topical and oral antivirals in the management of recurrent episodes of herpes labialis. In most countries, oral antivirals for herpes labialis are available as prescription-only. However, in early 2010, the oral antiviral famciclovir was reclassified from prescription-only medicine to pharmacist-controlled status in New Zealand. The benefits and risks associated with moving an antiviral therapy for herpes labialis from prescription-only to pharmacist-controlled status are reviewed here, and the implications for patients, general physicians and pharmacists are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.